Betamethasone valerate aerosol is a new compound for the treatment of asthma. Its clinical effectiveness was established in a double-blind cross-over trial in nonsteroid-dependent asthmatic patients. At a dosage of 400 to 800 tsg/day for three months there was no evidence of suppression of hypothalamic-pituitary-adrenal function, as assessed by tetracosactrin and insulin stress tests.
Introduction
Attempts to substitute inhaled corticosteroids for oral preparations in the treatment of asthma have until recently met with little success. Despite several early reports in which at least a modest response to inhaled powders of hydrocortisone and prednisolone was claimed, this route of administration has never found favour.
So far, only with beclomethasone dipropionate (Clark, 1972; Lal, 1972; Morrow Brown et al., 1972; Gaddie et al., 1973; Morrow Brown and Storey, 1973) has there been any indication that inhaled steroids may have an important part to play in the management of asthma. This compound has a high topical activity on the skin and apparently also in the lung, and it is effective in asthma in a dosage which is low enough to avoid the risk of suprarenal suppression. There have, however, been no adequate reports so far of its effect on the hypothalamicpituitary end of the axis. Another question that remains to be answered is whether undesirable side effects could emerge in the long term, particularly in respect of fungal infections of the respiratory tract. Betamethasone valerate is another halogenated corticosteroid which has a high topical potency relative to its systemic activity and which has not so far been assessed as an aerosol treatment for asthma.
This paper presents, in part A, a double-blind, cross-over trial with a three-month follow-up of inhaled betamethasone valerate compared with placebo and assessed by sequential analysis. We have attempted to establish its effectiveness in a dose which is without risk of hypothalamic-pituitary-adrenal (H.P.A.) suppression. H.P.A. function has been studied by tetracosactrin stimulation tests before and after four weeks, and by insulin stress tests after three months' treatment.
In part B we report a further and larger series of patients taking aerosol treatment with either beclomethasone dipropionate or betamethasone valerate whom we have followed up for 12 months. In this series we looked for long-term side effects with particular reference to fungal infections of the respiratory tract.
Part A-Clinical Trial of Betamethasone Valerate Aerosol
Patients Altogether 23 adults with daily, perennial moderately severe asthmatic symptoms who were not taking oral corticosteroids were admitted to the trial. Patients taking oral steroids during the previous three months were also excluded so that the full effect of the inhaled steroid on the H.P.A. axis could be assessed.
Five patients were withdrawn from the trial, two because of exacerbations of asthma needing oral steroid treatment during the introductory period, and three because they did not keep satisfactory records.
The patients studied in this cross-over trial were all asthmatics not dependent on steroids, and it might, therefore, be assumed that they had trivial symptoms. But this was not so, as 10 of them had readings for forced expiratory volume in one second of less than 50% of their predicted normal, and 12 of them had previously needed oral steroids to control their asthma. Indeed, if they had not responded to the steroid aerosol many of them would have needed long-term steroids by mouth. Ventilatory Function and Symptomatic Response.-The results obtained in the last 14 days only of each treatment period have been analysed in order to minimize any "carry-over" effect from the active treatment when it was given before the placebo. Sixteen of the 17 patients for whom daily peak flow readings were properly recorded had significantly higher readings on the active treatment, either in the morning, or in the evening, or both (table I). The mean daily peak flow readings for the group as a whole were also higher on active treatment (P <0 01). Symptom scores and bronchodilator requirements were both significantly reduced on the active treatment (P <0 01 and <0 05 respectively).
Suprarenal Function Tests.-The results of the short tetracosactrin tests were available before and after treatment in 17 patients. The responses were all normal according to the criteria of James and Landon (1969) . There were no differences between those measured immediately after the active aerosol and those after the placebo aerosol (table II) .
Failure to Respond to Betamethasone Valerate Aerosol.-Four patients (cases 2, 3, 7, and 18) failed to respond to the active treatment by one or more of the criteria. Their lack of response appeared to be unrelated to age, sex, age at onset, or duration of asthma, to the severity of the airways obstruction, and to the type of disease (extrinsic or intrinsic as determined by skin testing). The presence of sputum, however, probably influenced the outcome, as three of the four patients in whom it was noted (cases 2, 7, 14, and 18) were among the least responsive to treatment. Review after Three Months' Treatment.-At the end of three months five patients had stopped the treatment because they preferred bronchodilators and two had been lost to follow-up. The remaining 11 patients continued on maintenance steroid aerosol (three took 800 pg/day (cases 10, 11, and 12), six took 400 pg/day (cases 1, 5, 6, 13, 14, and 15), and two took 200 pg/ day (cases 16 and 17)). Good control of their asthma was maintained in all of them.
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Insulin Stress Tests were carried out in five of those on maintenance treatment (cases 5, 6, 10, 11, and 12) . After an intravenous injection in the fasting patient of 0-15 units/kg of soluble insulin at 9 a.m. the blood sugar was reduced to < 30 mg/100 ml. The criteria used for determining a normal response to hypoglycaemia were those of James and Landon (1969) (an increment of at least 7 pg/100 ml plasma cortisol and a final level of at least 20 ug). The response in all five patients was normal (table III) . In no patient was there any unpleasant effect from the test other then sweating and hunger. Pulse and blood pressure remained normal.
Side Effects.-No untoward side effects of the treatment were observed in nine of the patients. Two, who were taking 800 pg/day, however, developed sore throats and huskiness of the voice towards the end of the third month of treatment. On examination typical "thrush" lesions with white centres and red surrounds were seen on the fauces and posterior pharyngeal wall; in one (case 12) similar lesions were seen on the vocal cords, and in the other (case 11) the cords were reddened, but no white In patients where positive cultures for C. albicans were obtained, skin tests for immediate and delayed (24-hour) responses to candida extract were done when possible. The strengths used were 100 mg/ml for prick tests and both 1 mg/ml and 100 jsg/ml for intradermal tests (Bencard's extracts).
Results
Satisfactory long-term control of asthma was achieved in 88 out of the 120 patients. A maintenance dose of 200 tsg/day was adequate in all but 35 of these who required 300 to 400 ,g/day. Five patients, all children, required only 100 jug/day. These doses were arrived at by starting with 400 to 800 ,ug/day and lowering the dose after a full response had been achieved. This usually took less than four weeks, but efforts were made in the less responsive patients for up to three months.
Results of treatment and the incidence of fungal infections of the respiratory tract are set out in table IV. This is broken down to show the relation of oral steriod treatment to other factors. Temporary lack of response to steroid aerosol occurred in 15 patients during the course of upper respiratory tract infections with sputum (presumed to be viral), but these patients regained their good response in about three weeks. Other temporary lack of response occurred in four patients, who had specific extrinsic asthma, during heavy exposure to antigen. One during the grass pollen season, two who were sensitive to airborne fungal spores during the late summer, and one during exposure to house dust. These patients also recovered their response when they were no longer exposed to the respective antigens.
The prevalence of fungal infections of the respiratory tract was a problem. Sixteen patients (13%) developed infections of the pharynx or larynx or both with C. albicans; only nine of these were on oral steroid treatment, and none had recently been taking antibiotic drugs. The appearance of the lesions was typical of thrush and the most intense lesions were on the posterior pharyngeal wall. Fourteen of these patients also complained of severe soreness of the throat and huskiness of the voice, and two of them could hardly speak. In six patients (5%) white monilial spots were seen on the vocal cords on indirect laryngoscopy. There was no evidence that the infections involved the trachea or bronchi, though, of course, bronchoscopy could not be done to exclude this. No patient developed cough or wheeze which was thought to be due to the steroid aerosol and no radiological changes suggestive of fungal infections of the lungs were seen.
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Cultures from posterior pharyngeal throat swabs grew C. albicans in all 16 patients who admitted to sore throats. Swabs from a random 25 patients without symptoms were all negative.
The development of these candida infections may have been dose-related because we did not see them in any patients who were taking less than 400 jig/day of either aerosol. However, only two out of three patients in part A who had taken as much as 800 ,tg/day for 12 weeks became infected, whereas, in part B, four patients who started with only 400 ,4g/day developed candida infections in less than four weeks. All but five of the patients became symptom free and culture negative when the dose of steroid aerosol was reduced to 100 or 200 jug/day and amphotericin throat lozenges were taken, whereas the amphotericin had no effect on the patients before the aerosol dose was reduced. Five patients had to stop the aerosol before they recovered. The details of the 16 patients who developed candida infections are shown in table V. There did not appear to be a higher incidence of these infections in patients on oral steroids, in those taking disodium chromoglycate who might have had some pharyngeal and laryngeal irritation from this drug, or in female patients who could have been vaginal carriers of the organism.
The results of skin tests for both immediate and delayed sensitivity to candida were available in seven of the 16 patients (cases 1, 2, 3, 9, 11, 13, and 15). The immediate response was positive in all, and the late (24-hour) response was positive in all but one (case 15, who was taking oral steroids). Lymphocyte transformation tests were positive with candida extract in two patients who were examined for this (cases 2 and 9, who are also discussed in part A).
Discussion
The chance of success of steroid aerosol treatment in asthma depends on the choice of a compound with a topical activity which is high relative to its systemic activity. Both betamethasone valerate and beclomethasone dipropionate are such compounds.
There seems to be a popular misconception that these topicallyactive steroids are not absorbed through the lung or gut. This is untrue. Adrenal suppression has been found when large doses of both betamethasone valerate and of beclomethasone dipropionate are inhaled in man (4 mg and 2 mg respectively) (L. C. Wilson, personal communication, 1971; Choo-Kang et al., 1972) . Adrenal suppression has also been shown when large doses of betamethasone valerate are taken by mouth (8 mg/day) (Friedman et al., 1967) . It is therefore evident that these drugs are readily absorbed by both routes and that their absorption and systemic activity differ very little from that of the most commonly-used oral corticosteroid, prednisone. The virtue of the steroid aerosols lies simply in their very high topical activity, which enables them to be effective at a dose which is well below their H.P.A. suppressive level. It is apparent from the published work on beclomethasone dipropionate that non-steroid-dependent patients respond more readily to steroid aerosol than do those on maintenance oral treatment. Our experience has been the same in our long-term study. The reason for this better response in patients not dependent on steroids is not necessarily because their asthma may be less severe, but may be because they are less likely to have longstanding asthmatic disease with a large complement of fixed airways obstruction. Almost all of our failures of response to inhaled steroids were in patients with severe chronic asthma which was poorly controlled by as much as 15 mg/day of prednisone and in those with sputum. Most of these patients were steroid-dependent.
On the other hand, some of the most responsive patients were children with very severe asthma. These children might have been treated with oral corticosteroids by some Even if histological changes in the respiratory mucosa are absent it is possible that local immunological responses are altered. Sixteen (13%) of our patients developed pharyngeal thrush and in six (5%) of these the larynx was also involved. Though candida infections of the pharynx are sometimes seen in otherwise normal patients, particularly after antibiotic treatment, it is unusual to see candida in the larynx. This and other parts of the respiratory tract are seldom affected by this organism except in conditions of deficiency of cell-mediated immunity, in chronic mucocutaneous candidiasis, and in patients with terminal disease.
Of our 16 patients who developed candida infections seven were taking oral steroids and none had recently taken antibiotics. Also, no patient had shown any evidence of impairment of systemic immunological response. In view of these observations and the high prevalence of the infection in our series, we must suggest that steroid aerosols increase susceptibility to fungal infection of the pharynx and larynx. This could be due either to histological damage or to local immunological changes from the direct action of the topically-active steroid on the respiratory mucosa.
The development of laryngeal candidiasis is a cause for concern because it is not known how far down the respiratory tract the infection may penetrate. For this reason caution with steroid aerosols would seem advisable, particularly in respect of long-term high dosage, and we suggest that their use in patients with lung damage such as bronchiectasis, in which fungal infections could be difficult to eliminate, should be avoided until it can be established that the increased susceptibility to fungal infections does not involve the lung.
